GEN-MKT-18-7897-A
Feb 6, 2017 | Blogs, Forensic | 0 comments
As a forensic scientist, what holds you back in the lab? It’s a question we often ask ourselves here at SCIEX, as product development depends on customer wants, needs, satisfaction, and ease of workflow. Ensuring evidence can withstand forensic scrutiny, for example, correlates with the integrity of testing procedures. Knowing this, how do you convince your staff to be confident in results, or convey technical data to a non-technical courtroom audience? If you have been left wondering how to get to the bottom of topics like these, check out the following toxicology toolkit. It’s a bundle of resources at your fingertips that includes a webinar led by Tania A. Saski Ph.D., Northwest Physician Laboratories, Bellevue, Using QTRAP® Technology to Provide Accurate Identification and Confirmation Beyond a Reasonable Doubt, and so much more. Download Info Kit >
Tune in at your convenience to hear about her insights on four forensic cases with questionable results which were rectified using QTRAP® technology. When sample ratios are on the bubble and retention times vary, discover how LC-MS/MS can be a logical solution for difficult confirmations like opiate analysis. Gain higher confidence in your results and make it clear to everyone involved that you have a sample match.
In addition to the webinar, gain access to bundled application notes, a white paper, and in case you missed it, an e-seminar too. Want to get more insight into forensic applications? Visit, Border Security with Accuracy, Reliability, and Reproducibility.
Finding the right information shouldn’t slow you down. Whether you’re troubleshooting your mass spec, learning something new, or optimizing performance, access to the right resources at the right moment makes all the difference.
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
Posted by
You must be logged in to post a comment.
Share this post with your network